To differentiate roles of androgen receptor (AR) in prostate stromal and epithelial cells, we have generated inducible-(ind)ARKO-TRAMP and prostate epithelial-specific ARKO TRAMP (pes-ARKO-TRAMP) mouse models, in which the AR was knocked down in both prostate epithelium and stroma or was knocked out in the prostate epithelium, respectively. We found that loss of AR in both mouse models resulted in poorly differentiated androgen deprivation therapy ͉ testosterone ͉ TRAMP
To differentiate roles of androgen receptor (AR) in prostate stromal and epithelial cells, we have generated inducible-(ind)ARKO-TRAMP and prostate epithelial-specific ARKO TRAMP (pes-ARKO-TRAMP) mouse models, in which the AR was knocked down in both prostate epithelium and stroma or was knocked out in the prostate epithelium, respectively. We found that loss of AR in both mouse models resulted in poorly differentiated androgen deprivation therapy ͉ testosterone ͉ TRAMP E arly studies documented that prostate epithelial cell differentiation, proliferation, and apoptosis are regulated by androgen action through the prostatic stromal androgen receptor (AR) (1, 2) . In contrast, the prostatic epithelial AR might play little role as a result concluded from the mouse renal capsule-tissue recombination of normal prostatic stroma with testicular feminization syndrome (Tfm) epithelium (3) , in which the prostate develops and grows normally despite having a nonfunctional epithelial AR. These contrasting roles between the stromal AR and epithelial AR suggest the essential role of the stromal AR during initial prostate development (1) (2) (3) . However, the epithelial AR is required for the expression of some prostatic secretory proteins (4) , and prostatic epithelium induces smooth muscle differentiation of the stroma (4) . It was proposed that continuous reciprocal stromal-epithelial interaction enables mature prostate to maintain cellular homeostasis (5). Wu et al. (6) reported that specific ablation of the AR in mouse prostatic epithelium resulted in apoptosis of epithelial luminal cells and increased proliferation of epithelial basal cells in the ventral prostate, leading to enlargement of the gland. These dual roles of AR in stromal vs. epithelial cells may explain why the mature prostate maintains homeostasis without active proliferation in milieu rich in androgens.
The proliferation-stimulating role of AR is at the center of the premise for androgen deprivation therapy (ADT) for treating prostate cancer (7) . ADT with either surgical or medical castration usually results in a response rate of 70-80%, with Ϸ12-33 months duration of progression-free survival (8) . However, after an average of 24 months, the tumor almost always recurs and no longer responds to ADT (9) , even though the expression of AR in the prostate cancer remains unchanged (10) or is slightly increased (11) . Interestingly, cell sorting of these ADT-refractory tumors found that the prostatic epithelial basal cell marker, cytokeratin 5 (CK5), increased from 29% to 75% (12, 13) . The detailed mechanisms of how androgen/AR signals are altered and why cell populations changed after ADT remain unclear.
Using inducible-(ind)ARKO-TRAMP and prostate epithelialspecific ARKO TRAMP (pes-ARKO-TRAMP) mice, we found that the prostate stromal AR might play a more dominant role than the epithelial AR to promote primary tumor proliferation at an early stage of tumor progression. This unexpected result may help us to better understand the nearly invariable ultimate failure of ADT in achieving long-term tumor control and encourage us to develop new approaches that selectively (or preferentially) targets the stromal AR's proliferating role at earlier stages to treat prostate cancer.
classic concept that the AR functions as a proliferator in primary prostate tumor growth. We decided to further confirm these findings by in vivo orthotopic implantation of malignant prostatic epithelial and nonmalignant prostatic stromal cells. We coinoculated PC3-v or PC3-AR9 with stromal WPMY1-v cells that express the functional AR (16) and orthotopically implanted those stromal/ epithelial cells into the anterior prostates of nude mice. The results were consistent with Fig. 1 A showing addition of the functional AR in PC3-AR9 cells results in smaller primary prostate tumors after 12 wk (Fig. 1B) .
We then stably transfected AR-siRNA that can effectively knockdown endogenous AR (17, 18) into WPMY1 cells (designated WPMY1-ARsi). These WPMY1-ARsi cells were orthotopically coinoculated with either PC3-v or PC3-AR9 cells into the anterior prostates of nude mice. The results (Fig. 1B) showed that knockdown of the AR in stromal WPMY1-ARsi cells resulted in the suppression of primary prostate tumor growth (PC3-v ϩ WPMY1-v vs. PC3-v ϩ WPMY1-ARsi) and knockin of AR in PC3-AR9 cells resulted in the suppression of primary prostate tumor growth (PC3-v ϩ WPMY1-v vs. PC3-AR9 ϩ WPMY1-v). We performed H&E staining, which demonstrates that PC3-v ϩ WPMY1-v primary prostate tumors are larger and more poorly differentiated tumors compared with PC3-AR9 ϩ WPMY1-v tumors. The latter form lumen-like structures (Fig. 1B, H&E) , which can be due to the expression of AR in epithelial PC3 cells. We confirmed this phenotypic observation in a cell growth assay by staining with the proliferation marker Ki67 and found that the AR suppressed proliferation in the primary prostate tumors developing from these PC3-AR9 xenografts (Fig. 1B) . Together, we clearly demonstrated that the AR could function as either a suppressor or a proliferator depending on its location for primary prostate tumor growth. Because of the expression of AR in PC3-AR9, as driven by the AR natural promoter, in vitro growth of PC3-AR9 is slightly increased in the presence of 1 nM 5␣-dihydrotestosterone (15) . However, with PC3-v cells, we found that in vivo orthotopicimplanted PC3-AR9 tumors form smaller primary tumors (Fig. 1) . The possible explanation for these different in vivo and in vitro findings could be that the in vivo observation is a relatively long-term condition, and primary tumor growth could be influenced by the prostate cell microenvironment and stroma-derived factors, whereas in vitro growth is under a simplified, twodimension, nonphysiological condition. Our results suggest that the long-term comparison of in vivo tumor cell growth may lead to more accurate assessment than the short term in vitro growth assay. Because the above in vivo data were generated from orthotopically coimplanted human prostate epithelial tumor (CK5/CK8-positive PC3 cells) and human stromal (WPMY1-v) cell lines in nude mouse, we developed a different strategy using mice that can spontaneously develop prostate tumor as another in vivo animal model to confirm our findings. We first generated pes-ARKO mice that lack the AR only in the prostatic epithelium and demonstrated that loss of the epithelial AR resulted in increased prostatic epithelial cell proliferation (6) . We then used floxAR mice (19) to generate pes-ARKO-TRAMP mice that spontaneously developed prostate tumors lacking AR in tumor epithelial cells [supporting information (SI) Fig. S1 ]. We also generated ind-ARKO-TRAMP mice in which prostatic AR could be knocked down in both the epithelium and stroma (Figs. S1 and S2)
The ind-ARKO-TRAMP mice can be induced by pI-pC to delete the floxed AR gene in whole body, including prostate epithelium and stroma. The rationale for establishing ind-ARKO-TRAMP mouse is to mimic the condition in human prostate cancer patients treated with ADT. This ind-ARKO-TRAMP mouse has the reduced AR expression in prostate epithelium and stroma ( and reduced serum androgen levels. The advantage of using this model is that AR knockout could be controlled at given time points by pI-pC injections, for example, at 4 wk (before tumor initiation), 12 wk (PIN stage), or 20 wk (tumor progression). More importantly, it allows us to compare the effects of reduced AR in both prostate epithelium and stroma vs. reduced epithelial AR only in pes-ARKO-TRAMP mice.
Serum Testosterone, Prostate Size, and Cell Population Changes in pes-ARKO-TRAMP and ind-ARKO-TRAMP Mice. Except for the larger primary prostate tumors found in pes-ARKO-TRAMP mice, we found the reproductive organs are similar between pes-ARKO-TRAMP mice and their WT TRAMP male littermates ( Fig. 2A) . In contrast, ind-ARKO-TRAMP mice had smaller reproductive organs and prostates as compared with their WT TRAMP littermates ( Fig. 2 A) . Serum testosterone remained similar between pes-ARKO-TRAMP mice and their WT TRAMP littermates. However, serum testosterone was reduced from 16 to 24 wk in ind-ARKO-TRAMP mice that were injected with pI-pC at 12 wk old (Fig. 2B) . The observation of larger primary prostate tumors with similar serum testosterone in pes-ARKO-TRAMP mice, as compared with WT TRAMP mice, suggests that serum testosterone may not be a good marker to predict primary prostate tumor growth. Early epidemiological studies also indicated there is little linkage between serum testosterone and prostate cancer risk (20) . Moreover, several other studies found that lower serum testosterone levels were associated with more advanced and poorly differentiated tumors (21, 22) . Furthermore, among the three types of Interestingly, because the AR can regulate the expression of PB promoter-derived SV 40 T antigen, this argues that ARKO-TRAMP mouse may have reduced expression of SV 40 T antigen and thus reduce the tumorigenicity or tumor progression. However, we observed the faster primary tumor growth in pes-ARKO-TRAMP mice as compared with the littermate WT TRAMP mice, suggesting the faster growth of primary tumor in pes-ARKO-TRAMP mice may be little influenced by the reduction of SV 40 T antigen expression in prostate. It is possible that the initial SV 40 T antigen expression, before knockout of AR, is sufficient to promote the tumor initiation and continuing progression.
To date, there is still a lack of a perfect mouse model to mimic perfectly the human prostate cancer. For example, the Pten-KO mouse model has almost 100% CD44 positive prostate cancer cells, yet there are only limited CD44-positive cells in human prostate cancer. Moreover, several reports have documented that Pten could modulate AR function directly or indirectly (via PI3K), and loss of the Pten could consequently change the AR function, which would confound interpretation of the data. Furthermore, we have a parallel study to evaluate tumor growth in 16-wk-old TRAMP mice under ADT conditions via inducing AR knockdown in both stroma and epithelium (ind-ARKO-TRAMP) that results in the decreased tumor volumes with increased apoptosis. These data are consistent with clinical studies demonstrating that ADT, which antagonizes both stromal and epithelial AR, reduces tumor volume and increases apoptosis. Because the PB promoter was used to drive SV 40 T antigen and cre expression in pes-ARKO-TRAMP mice, both SV 40 T antigen and cre transgenes were expected to express in the same cell.
Increased vs. Decreased Primary Prostate Tumor Growth in pes-ARKO-
TRAMP and ind-ARKO-TRAMP Mice. We found larger primary prostate tumors in 16-, 20-, and 24-wk-old pes-ARKO-TRAMP mice than in their WT TRAMP littermates. In contrast, in 16-wk-old ind-ARKO-TRAMP mice, we found smaller primary prostate tumors than in their WT littermates after injection with pI-pC at 12 wk old. (Fig. 4 A and B) . With H&E staining, we also observed that primary prostate tumors in pes-ARKO-TRAMP mice were poorly differentiated as compared with their WT littermates at the age of 16 or 20 wk (Fig. 4A, H&E) , suggesting primary tumors in pes-ARKO-TRAMP mice may have more aggressive behavior as compared with tumors in their WT TRAMP littermates. Notably, the smaller primary prostate tumors found in ind-ARKO-TRAMP mice were also poorly differentiated as compared with tumors in their WT TRAMP littermates (Fig. 4A) , further confirming that the expanded population of intermediate-like tumor cells could result in poorly differentiated tumors in these mice. To correlate the increased tumor size with proliferating rates in the primary prostate tumors, we assayed proliferation rates via Ki67 and BrdU stainings. We found substantially higher Ki67 staining and higher BrdU incorporation rates in primary prostate tumors of pes-ARKO-TRAMP mice than those in their WT TRAMP littermates (23) . In contrast, we found less Ki67 staining and BrdU incorporation rates in primary prostate tumors of ind-ARKO-TRAMP mice compared with those in their WT TRAMP littermates (Fig. 4C) . With double staining of proliferation marker BrdU and basal cell marker CK5, we confirmed the cells with higher proliferation rates are basal-intermediate cells in primary prostate tumors of pes-ARKO-TRAMP mice (23) and lower proliferation rates in those basal-intermediate cells in tumors from ind-ARKO-TRAMP mice than those from their WT TRAMP littermates (Fig.  4D) . Interestingly, although basal-intermediate cell populations expanded in tumors of pes-ARKO-TRAMP and ind-ARKO-TRAMP mice, the proliferation rates of these basal-intermediate cells were higher in primary prostate tumors from pes-ARKO-TRAMP mice, indicating prostate stromal AR may play a more dominant stimulating role in primary prostate tumor growth. Together, we found larger and more aggressive primary prostate tumors with higher proliferation rates in pes-ARKO-TRAMP mice and smaller primary prostate tumors with lower proliferation rates in ind-ARKO-TRAMP mice as compared with those in littermate WT TRAMP mice. 
Ind-ARKO-TRAMP Mice Develop Less Aggressive and Invasive Metastatic Tumors.
We also compared metastatic tumor size in 24-wk-old pes-ARKO-TRAMP mice, WT TRAMP mice (with or without injection of pI-pC at 12 wk old), and ind-ARKO-TRAMP mice (injected with pI-pC at 12 wk old), our results indicated pes-ARKO-TRAMP mice developed larger and histologically more aggressive metastatic tumors in lymph nodes as compared with their WT littermates (Fig. 5A) . In contrast, knockdown of the AR in both epithelial and stromal cells in ind-ARKO-TRAMP mice led to smaller and less-aggressive metastatic tumors in lymph nodes as compared with their WT TRAMP littermates injected with pI-pC (Fig. 5A) .
Because prostate tumors developed at different rates between pes-ARKO-TRAMP mice and ind-ARKO-TRAMP mice, we took another approach to compare the development of primary tumors between these two different ARKO mice. We found pes-ARKO-TRAMP mice required 18 wk to develop a primary prostate tumor with size near 1 cm in diameter. However, it took 36 wk for ind-ARKO-TRAMP to develop similarly sized primary prostate tumors (Fig. 5B) . Moreover, histological analysis of prostate primary tumors of similar size from pes-ARKO-TRAMP at 18 wk old and ind-ARKO TRAMP mice at 36 wk old demonstrated more aggressive appearing primary tumors in pes-ARKO-TRAMP mice (Fig. 5C ). Furthermore, pes-ARKO-TRAMP mouse tumors metastasized to pelvic lymph nodes, and ind-ARKO-TRAMP mouse tumors metastasized to lung, kidney, and liver when primary tumors grew to 1 cm in diameter (Fig. 5B) .
The larger and more-aggressive primary and metastatic tumors in pes-ARKO-TRAMP mice may then lead to earlier death than in WT TRAMP littermates (Fig. 5D) . In contrast, the smaller and less-proliferative primary and metastatic prostate tumors in ind-ARKO-TRAMP mice may result in longer lives compared with their WT TRAMP littermates (Fig. 5D) .
These results suggest that stromal AR functions as a proliferator and may play a dominant role for the primary prostate tumor growth. Other studies also demonstrate that stromal cells play vital roles in prostate carcinogenesis and metastasis. For example, alteration of stromal TGF␤ signals have been demonstrated to play a key initiating role in prostate carcinogenesis in mice lacking the stromal TGF␤ receptor II (25) . Stromal cells isolated from cancerous tissues also elicited irreversible malignant transformation of the human epithelia and that TGF␤ stimulates this cell transformation (26) . Finally, bone marrow stroma cells have been demonstrated to establish a prometastatic niche ''soil'' in which circulating metastatic prostate cancer cells can preferentially grow (27, 28) . Together, these data suggest that the stromal cells may be able to promote prostate primary tumor growth and migration to distant tissues and stromal AR play critical roles in those processes.
Impact to Current Clinical Treatment of Prostate Cancer. The conclusions drawn from above data may influence clinical prostate cancer therapy. Based on our findings, we believe the ideal therapeutic approach to battle androgen sensitive prostate tumors would be to target stromal AR at earlier stages, perhaps via a stromalspecific delivery system that delivers AR-siRNA or a compound, such as ASC-J9 (29) , to suppress or degrade the AR in stromal cells only. Unfortunately, no such stromal-specific delivery system has been developed. However, because of the unique surface antigens expressed by prostatic stroma, such an approach may be possible in the future. Nevertheless, even if we can target only the whole AR as in the ind-ARKO-TRAMP mouse model, we may still be able to battle prostate cancer with better timing. Based on our ind-ARKO-TRAMP mouse model that targeted the AR at different times, we found the earlier targeting of the AR via knockdown of AR (at 4 wk) results in a much better suppression of primary prostate tumor growth than that occurred with later targeting (at 20 wk) ( Table 1 gen/AR functions in both stromal and epithelial cells, which may be the reason why tumors of prostate cancer patients were suppressed at the beginning of treatment and then have a recurrence after ADT treatment (30) . Therefore, it will be interesting to see whether selectively targeting the stromal AR at earlier stages can become a better strategy to battle prostate cancer.
Methods
Establishment of Stable Transfected WPMY1-ARsi Cells. We constructed a siRNA into retroviral pSuperior vector to target human AR mRNA sequence 5Ј-gtggccgccagcaaggggctg-3Ј (1530 -1550). This pSuperior ARsiRNA was used to infect human stromal WPMY1 cells to establish WPMY1-ARsi cells. Diameter of primary prostatic tumor or lymph node metastatic tumor; data are presented as mean Ϯ SD mm. *P Ͻ 0.05.
Orthotopic Implantation of Prostate
We verified the genotypes by PCR using tail snip DNA as templates. We found that both WT-TRAMP and ind-ARKO-TRAMP mice showed T-ag bands (Fig. S1b Top) , whereas only ind-ARKO-TRAMP mice had floxed AR bands (Fig. S1b  Middle) and Mx-Cre bands (Fig. S1b Bottom) . We confirmed the knockdown of AR in ind-ARKO-TRAMP mice by detecting the mRNA with deletion of AR-exon 2 in different organs, such as AP, DLP, VP, seminal vesicle (SV) (Fig. S1c) , liver, spleen, and testis (data not shown).
We monitored the knockdown efficiency in the ind-ARKO-TRAMP mice that were injected with pI-pC at 12 wk, and found AR mRNA was knocked down by 40-50% in prostate, 40% in testis, 20% in SV, and 80% in liver of both 16-wk-old and 20-wk-old mice (Fig. S2a) . We used immunohistochemical staining of AR to confirm the knockdown of AR in both epithelium and stroma of 16-wk-old ind-ARKO-TRAMP mice (Fig. S2b) . We measured AR mRNA from LCM-isolated epithelium or stroma of 16-wk-old ind-ARKO-TRAMP mice to confirm the loss of 60% AR mRNA in epithelium and 50% AR mRNA in stromal cells as compared with their pI-pC injected WT-TRAMP littermates (Fig. S2c) . We used genotype screening of mice from tail snip DNA and T-ag (SV40) primer to identify TRAMP mice at 4 wks old (Top). We used primers ''2-3'' and ''select'' [Yeh S, et al. (2002) Generation and characterization of androgen receptor knockout (ARKO) mice: An in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci USA 99:13498 -13503] that amplify AR-exon 2 and the surrounding intron region to identify the floxed AR allele in pes-ARKO-TRAMP mice and ind-ARKO-TRAMP mice (Middle). We used primers specific for Pb-Cre and Mx-Cre to identify Pb-Cre and Mx-Cre transgenic mice, respectively (Bottom). (c) We confirmed AR knockout by detecting the exon 2 deletion in AR mRNA, using exon 1 and exon 3 primers, specific ARKO bands by RT-PCR amplifying AR mRNA from different organs. In pes-ARKO-TRAMP mice, we showed ARKO bands in dorsal lateral prostate (DLP), ventral prostate (VP) and anterior prostate (AP), but no significant band in seminal vesicles (SV) compared to Wt-TRAMP. In ind-ARKO-TRAMP mice, we found ARKO bands in DLP, VP, AP, and SV. S2. (a) We performed pI-pC injection at the age of 12 wks. At the age of 4 wks and 8 wks following pI-pC injection (at 16-wk-old and 20-wk-old), we determined AR knockdown in different organs at various degrees by using Real-time RT-PCR to detect relative expression levels of AR-exon 2 mRNA. (b) IHC AR staining showed AR protein was partially lost in ventral prostate epithelium (white arrows) and stroma (black arrows) of ind-ARKO-TRAMP mice compared to WT-TRAMP mice at 16-wk-old. (c) We demonstrated that the AR was partially knocked down in both the epithelium (ind-ARKO-epi) and stroma (ind-ARKO-str), separated by LCM, in ventral prostate of ind-ARKO-TRAMP mice using real-time RT-PCR of AR-exon 2.
